ScoreWhy is Zevra Therapeutics, Inc. ?
1
With a growth in Operating Profit of 392.61%, the company declared Outstanding results in Mar 26
- The company has declared positive results for the last 5 consecutive quarters
- NET PROFIT(HY) At USD 52.5 MM has Grown at 227.97%
- OPERATING CASH FLOW(Y) Highest at USD 12.77 MM
- ROCE(HY) Highest at 99.11%
2
With ROE of 89.05%, it has a very attractive valuation with a 3.48 Price to Book Value
- Over the past year, while the stock has generated a return of 42.23%, its profits have risen by 228.1% ; the PEG ratio of the company is 0
3
High Institutional Holdings at 82.89%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating performance in long term as well as near term
- Along with generating 42.23% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Zevra Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Zevra Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Zevra Therapeutics, Inc.
42.23%
2.82
63.05%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
51.61%
EBIT Growth (5y)
4.50%
EBIT to Interest (avg)
-14.46
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.05
Sales to Capital Employed (avg)
0.31
Tax Ratio
22.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
82.89%
ROCE (avg)
10.83%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
4
Industry P/E
Price to Book Value
3.48
EV to EBIT
-96.65
EV to EBITDA
-409.13
EV to Capital Employed
15.74
EV to Sales
3.84
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
-16.29%
ROE (Latest)
89.05%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend30What is working for the Company
NET PROFIT(HY)
At USD 52.5 MM has Grown at 227.97%
OPERATING CASH FLOW(Y)
Highest at USD 12.77 MM
ROCE(HY)
Highest at 99.11%
NET SALES(Q)
Highest at USD 36.22 MM
RAW MATERIAL COST(Y)
Fallen by -9.78% (YoY
CASH AND EQV(HY)
Highest at USD 391.63 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 7.05 times
PRE-TAX PROFIT(Q)
At USD 54.02 MM has Grown at 51.05%
-2What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Zevra Therapeutics, Inc.
Net Profit
At USD 52.5 MM has Grown at 227.97%
Year on Year (YoY)MOJO Watch
Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Highest at USD 36.22 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Sales
At USD 36.22 MM has Grown at 36.08%
over average net sales of the previous four periods of USD 26.62 MMMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD 12.77 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Pre-Tax Profit
At USD 54.02 MM has Grown at 51.05%
over average net sales of the previous four periods of USD 35.77 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Cash and Eqv
Highest at USD 391.63 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debtors Turnover Ratio
Highest at 7.05 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -9.78% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
